DURECT Corp (DRRX): Price/Earnings to Growth Ratio

Symbol and logo of brand DURECT Corporation (DRRX)

Risks for DURECT Corporation (DRRX) are tied to clinical trial outcomes and liquidity shortages. The PEG fair value filter clearly demonstrates the valuation trend, where the current value equals 0.00. This correlates with plans to launch an alcoholic hepatitis therapy in the US market and strict adherence to bioethical ESG standards regarding chemical waste disposal in laboratories.

DURECT (DRRX): Price/Earnings to Growth Multiple from 07/04/2022 to 09/27/2025

Metric breakdowns and analytics for DURECT Corporation (DRRX)

- share price and consensus valuation forecast:
Price Performance Chart durect.com|DRRX - Price Target Chart
- stock exchange capitalization data:
Market Value DURECT Corp.|DRRX - Enterprise Value
- issuer book value statistics:
Net Assets per Share DURECT|DRRX - Company Net Assets|Market Value to Book Value Ratio durect.com|DRRX - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Capital DURECT Corporation|DRRX - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital durect.com|DRRX - Company Aggregate Debts|Debt to Book Value Ratio DURECT Corp.|DRRX - Company Long-Term Liabilities|Company Short-Term Debts DURECT|Intermediate Coverage Ratio durect.com
- net income and valuation ratios data:
DRRX - Net Profit|Expected Net Profit DURECT Corporation|DRRX - P/E Multiple|Projected Price to Earnings durect.com|DRRX - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio DURECT Corp.|DRRX - Operating profit before deduction of amortization|Earnings per share for the trailing year DURECT|DRRX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months durect.com|DRRX - Earnings per share growth in current year|Expected net earnings per share growth next year DURECT Corporation
General company analysis:DURECT Corp (DRRX)
Mass-produced product of DURECT

Establishing a long-term position requires strict control over the balance between market price and earnings dynamics. The operational capacity of DURECT Corporation (DRRX) is evidenced by the full utilization of certified laboratories dedicated to developing liver therapy drugs. This growth company undervaluation metric compares the P/E ratio with business expansion rates. Values below one signal a fundamental undervaluation of the asset relative to its potential. A stable indicator confirms the high resilience of the issuer's business model.

Who DURECT Corporation competes with

ARWR (Arrowhead Pharma) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Mirum Pharma MIRM|Dynavax - Price/Earnings to Growth Ratio|Arbutus Biopharma - PEG Multiple|Growth-Adjusted Market Cap to Net Income inventivapharma.com IVA|GYRE (Gyre Therapeutics) - Price/Earnings to Growth Multiple|ASMB (Assembly Bio) - Price/Earnings to Growth Ratio|GALT (Galectin Therapeutics, Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Genfit Corp GNFT|Price/Earnings to Growth Ratio Aligos Therapeutics (ALGS)|BIVI (biovieinc.com) - Growth-Adjusted Payback Ratio|PEG Multiple GLMD (Galmed Pharmaceuticals Ltd.)|NDRA: Growth-Adjusted P/E Ratio|HEPA: Price/Earnings to Growth Multiple